Dixon Technologies gets CCI nod for 56% Ismartu buy

What the CCI approval changes for the deal

Dixon Technologies (India) Ltd has received clearance from the Competition Commission of India (CCI) for its proposed acquisition of a majority stake in Ismartu India Private Limited. The approval, disclosed through a stock exchange filing, updates Dixon’s earlier intimation dated April 8, 2024.

CCI cleared the proposed combination in its meeting held on July 18, 2024. The regulator approved the transaction under sub-section (1) of Section 31 of the Competition Act, 2002, and recorded it as Comb Reg no. C-2024/04/1137. The approval allows Dixon to acquire up to 56% shareholding in Ismartu India.

The acquisition structure: two tranches

The transaction is structured in two phases through a share purchase agreement. Dixon has stated that it will acquire 50.10% stake in the first tranche, with additional stake to be acquired later under a second tranche.

After the second tranche, Dixon will hold a minimum of 51.70% and, at its option, a maximum of 56% in Ismartu India. The final percentage depends on the extent of Tranche II acquisition.

Tranche I: 50.1% for Rs 238.36 crore in cash

In the first tranche, Dixon will purchase 50.1% of Ismartu India for an aggregate initial consideration of Rs 238.36 crore, in an all-cash deal. The company noted that the consideration is subject to pre-closing and post-closing adjustments in accordance with the terms of the share purchase agreement.

Dixon also disclosed that this purchase corresponds to 1,38,73,846 equity shares of Ismartu India. The sellers named for Tranche I include Ismartu Singapore, Transsion Technology Limited, and 5A Advisors LLP.

Tranche II: FY 2026-27 purchase with valuation linked to PAT

Dixon has rights to acquire an additional stake ranging from 1.60% to 5.90% in Ismartu India. The company said this second tranche is expected to be done in financial year 2026-27.

For Tranche II, Dixon stated the aggregate consideration will be determined based on a valuation of 20 times the profit after tax (PAT) of the target company for FY 2025-26. The deal terms, as described, tie the second tranche pricing to Ismartu India’s FY 2025-26 profitability.

Performance condition mentioned for the second tranche

Dixon’s exchange filing noted that the option for the additional stake depends on the company’s performance in FY 2025-26. It also said the second tranche will be contingent upon Ismartu India achieving Rs 200 crore.

The company has not, in the provided details, specified the exact nature of the Rs 200 crore threshold. The condition is described as part of the performance-linked approach for Tranche II.

Who is Ismartu India and what it makes

Ismartu India is described as being engaged in electronics and mobile devices manufacturing. It has also been described as an EMS provider specialising in mobile phones and ancillary services under the brands Itel, Infinix, and Tecno.

The business is also referred to as a manufacturing unit of Chinese phone maker Transsion Holdings, linking Ismartu India to a broader mobile handset ecosystem focused on mass-market smartphone brands.

Dixon’s EMS portfolio and why this asset fits

Dixon Technologies is a contract manufacturer that provides electronic manufacturing services across multiple product categories. The company has been described as providing EMS for lighting solutions, televisions, washing machines, security systems, and wearables.

Against that backdrop, Ismartu India’s capabilities in mobile phones and related services sit within a segment where scale, speed of execution, and manufacturing consistency can matter for winning and retaining brand programs.

Key regulatory details disclosed by the company

The CCI clearance is an important condition referenced in Dixon’s exchange filing. The company stated that acquisition of Tranche I and Tranche II shares is subject to satisfactory completion of conditions precedent set out in the share purchase agreement, and is subject to approval of the Competition Commission of India.

With the July 18, 2024 decision, the CCI condition referenced in the filing has now been met, based on the information provided. The regulator also issued a release stating it has approved the acquisition of up to 56% shareholding of Ismartu India Private Ltd by Dixon Technologies (India) Ltd.

Deal snapshot

Market impact: what investors can take away from the disclosures

The disclosures primarily clarify transaction mechanics, timing, and regulatory status, rather than near-term financial impact. The only explicit cash outflow stated for now is the Tranche I consideration of Rs 238.36 crore, with Tranche II pricing linked to FY 2025-26 profitability through a 20x PAT valuation framework.

The CCI approval reduces a key closing uncertainty for the proposed combination, since competition clearance was a stated requirement in the company’s filing. Beyond that, the company has not provided additional metrics in the material shared here, such as Ismartu India’s revenue, PAT, or capacity numbers, so the financial contribution cannot be quantified from these details alone.

Why the development matters for India’s EMS landscape

The transaction underscores continuing consolidation and capability-building within India’s electronics manufacturing services space, particularly in mobile phones and related supply chains. For Dixon, the proposed purchase extends its stated EMS presence across categories into a deeper exposure to mobile device manufacturing through a majority stake structure.

For Ismartu India, the proposed arrangement brings in a large listed EMS player as a majority shareholder, with the second tranche explicitly tied to performance in FY 2025-26 and executed in FY 2026-27. The staged structure also indicates how both sides are linking ownership expansion to business outcomes and valuation discipline.

What to watch next

Dixon has already stated that both tranches are subject to completion of conditions precedent set out in the share purchase agreement. With CCI approval now in place, the next updates are likely to revolve around progress toward closing Tranche I and, later, the FY 2026-27 timetable and performance-linked terms that determine the extent of Tranche II.

The company has also specified the post-Tranche II ownership band of 51.70% to 56%, which will depend on the eventual additional stake acquired. Investors will look for further exchange disclosures as those steps move forward.